

- Acepromazine, 136, 137t  
     drug combinations with, 140–41, 140t, 141t  
     equine preanesthetic sedative with, 363  
     geriatric patients premedication with, 277–78, 280t  
     induction with, 149  
     pediatric patients premedication with, 269, 270t
- Acetaminophen, 352
- Acupuncture, pain management with, 353–54
- Acute pain, 326
- Adaptive pain, management of, 347–50  
     alpha-2 agonists for, 347–49  
     local anesthetics for, 349–50, 350f  
     NMDA receptor antagonists for, 348–49  
     nonsteroidal antiinflammatory drugs for, 347  
     opioids for, 348, 349f, 349t  
     tramadol for, 348
- Addison's disease. *See* Hypoadrenocorticism
- ADH. *See* Antidiuretic hormone
- Adjunctive analgesics drugs, 16
- Adjustable pressure limiting valve (APL valve), 76
- ADT. *See* Advanced diagnostic testing
- Advanced diagnostic testing (ADT), 21–22  
     blood glucose, 22  
     BUN serum test, 22, 249  
     complete blood count, 22  
     complications with, 168  
     creatinine serum test, 22, 249  
     full chemistry profile, 22  
     packed cell volume, 22  
     total plasma protein, 22  
     urine specific gravity, 22
- Advance life support, cardiopulmonary/cerebral resuscitation with, 178
- Afferent nerve fibers, 327–28, 328t
- A-fib. *See* Atrial fibrillation
- Afterload, 5
- Agent dose calculation, 30–31, 31t
- Agent strength percent solution calculations, 30
- Airway maintenance, 57–70  
     cleaning and sterilization with, 67–70  
     complications with, 67, 68t  
     endotracheal tubes v. facemask for, 58t  
     extubation for, 66–67, 67t  
         three-way stopcock with, 66, 67t  
     intubation for, 63–66, 63f  
         assistant holds head for, 63, 63f  
         cuff inflation guidelines with, 65t  
         guidelines for success with, 63t  
         laryngospasm with, 64t  
         placement confirmation with, 66t  
         tube tie with, 66t  
     intubation supplies for, 61–63  
         laryngoscopes, 61–62, 62f  
         stylet and guide tubes, 62–63, 62f  
     selecting appropriate tube for, 60–61  
     special endotracheal tubes for, 58–59, 59f  
     tube design for, 59–60, 60f  
     tube storage with, 67–70, 69f  
     types of endotracheal tubes for, 57–58, 58f
- Airway management, cardiopulmonary/cerebral resuscitation with, 175
- Airway obstruction  
     anesthesia complicated by, 170–71  
     capnograph showing, 117f
- Alanine aminotransferase (ALT), 22
- Albumin, 124–25
- Alfaxalone, pediatric patients induction with, 270t, 271
- Alkaline phosphatase serum tests, 22
- Alpha-2 agonists, 137–38  
     adaptive pain management with, 347–48  
     cardiovascular effects from, 215t  
     liver disease pharmacology with, 259–60  
     pediatric patients premedication with, 269  
     renal disease anesthesia with, 251, 253t
- ALT. *See* Alanine aminotransferase
- Alveolar-capillary membrane, 8
- Alveolar ventilation, 8, 9
- Alveoli, 7, 8f
- Amantadine, pain management with, 352
- American Society of Anesthesiologists (ASA), 20  
     status, 20–21, 21f
- Amidate. *See* Etomidate
- Aminotransferases, 22
- Analgesics, 16  
     recovering patient with, 165
- Anatomic dead space, 9, 10f, 113
- Anesthesia equipment, 71–84  
     anesthetic delivery, 73–75, 74f, 75f

- blood pressure monitoring, 119–20
- breathing systems, 80–84, 81f, 82f
  - fresh gas flow rates, 83
  - low-flow circle, 83–84
  - nonrebreathing, 81–83, 82f
  - rebreathing, 80–81, 81f
  - reservoir bag, 83
  - selection of, 84
  - semiclosed circle, 84
- carbon dioxide removal, 75–76
  - APL valve, 76, 168
  - carbon dioxide absorber canister, 75, 168
  - one-way valves, 75–76
- complications with, 168
- correcting problems in, 80
- end-tidal carbon dioxide monitoring, 119–20
- functional components, 71–76, 72f, 74f, 75f
- oxygen delivery, 71–73, 72f
- performing pressure test for, 78–79
- troubleshooting after procedure with, 80
- troubleshooting before procedure with, 77–78
  - breathing bags/circuit, 78
  - breathing system, 77
  - one-way valves, 77
  - oxygen supply, 77
  - sodalime canister, 77–78
  - WAG tubing/connections, 78
- troubleshooting during procedure with, 79, 79f
- vaporizers, 73–75, 74f, 75f
  - complications with, 168
- waste anesthetic gas removal, 76–77, 76f
  - active system, 76–77, 76f
  - passive system, 76
- Anesthesiologist Society of America (ASA)
  - heart disease patients classified by, 207t
  - physical status scale from, 85
- Anesthetic depth monitoring, 101–3, 101f–103f
  - Capillary Refill Time in, 101–2, 102f
  - corneal reflex in, 101, 101f
  - esophageal stethoscope in, 102–3, 103f
  - jaw tone in, 101, 102f
  - mucus membrane color in, 101
  - palpation of arteries in, 102, 102f
  - palpebral reflex in, 101
  - position of eye in, 101
  - swallowing reflex in, 101
  - withdrawal reflex in, 101, 101f
- Anesthetic record, 35–37, 36f
  - automated, 37
  - handwritten monitoring grid, 37
  - information included in, 35
  - legal document, 37
- Antibiotics, 16
- Anticholinergics, 136
  - cardiovascular effects from, 215t
  - pediatric patients premedication with, 269, 270t
  - renal disease anesthesia with, 251, 253t
- Antidiuretic hormone (ADH), 248–49
- Aortic stenosis, 212, 214t
- APC. *See* Atrial fibrillation premature complex
- APL valve. *See* Adjustable pressure limiting valve
- Apnea, anesthesia complicated by, 170
- Arrhythmias, 5, 88
  - anesthesia complicated by, 173
  - supraventricular, 213, 217t
- Arterial blood gases, 24
- ASA. *See* Anesthesiologist Society of America
- Aspartate aminotransferase (AST), 22
- Aspiration, anesthesia complicated by, 169–70
- AST. *See* Aspartate aminotransferase
- Atelectasis, 8, 189
- Atipamezole, cardiopulmonary/cerebral resuscitation with, 180t
- Atracurium, neuromuscular blockade with, 199
- Atrial fibrillation (A-fib), 91
- Atrial fibrillation premature complex (APC), 91, 213
- Atrial standstill, 217
- Atrioventricular block (AV block), 4, 89–90, 89f
  - 1st degree, 89, 216, 217t
  - 2nd degree, 89, 89f, 216, 217t
  - 3rd degree, 90, 216–17, 217t
- Atrioventricular node (AV node), 3
- Atropine, 136, 137t
  - cardiopulmonary/cerebral resuscitation with, 178–79, 180t
  - equine preanesthetic sedative with, 363
  - geriatric doses for, 280t
  - pediatric doses for, 270t
- Auriculopalpebral nerve block, 374
- AV block. *See* Atrioventricular block
- AV node. *See* Atrioventricular node
- BAG (butorphanol, acepromazine, glycopyrrolate), 140–41, 140f
- Bain Coaxial system, 82, 82f
- Bandage placement, 164
- Barbiturates
  - cerebral blood flow with injectable, 222
  - induction with, 147–49
  - liver disease pharmacology with, 260
  - renal disease anesthesia with, 252, 253t
- Base deficit, 93
- Base excess (BE), 93
- Basic minimum database (BMD), 21
- BE. *See* Base excess
- Benzodiazepines, 136–37
  - cardiovascular effects from, 215t
  - cerebral blood flow with injectable, 222
  - geriatric patients premedication with, 277, 280t
  - induction with, 144–45

- liver disease pharmacology with, 259–60
- pediatric patients premedication with, 269, 270t
- renal disease anesthesia with, 251, 253t
- Bicarbonate level ( $\text{HCO}_3$ ), 93
- Blood gas analysis, 91–93
  - components of, 92–93
    - base excess/base deficit, 93
    - bicarbonate level, 93
    - end-tidal carbon dioxide, 92
    - oxygen saturation, 92–93
    - partial pressure of carbon dioxide, 92
    - partial pressure of oxygen, 92
    - pH, 92
  - errors in sampling with, 93
  - physiology with, 92
  - sample collection for, 93
- Blood glucose, 22
- Blood pressure, 5–7
  - diastolic, 5, 106, 107t
  - direct (invasive) monitoring of, 107–10, 109f
    - arterial catheter used for, 108
    - selecting catheter site for, 108
    - troubleshooting, 109–10
    - waveform interpretation for, 108, 109f
  - factors determining, 106, 106f
    - cardiac output as, 106, 106f
    - heart rate as, 106, 106f
    - stroke volume as, 106, 106f
    - total peripheral resistance as, 106
  - indirect (noninvasive) monitoring of, 110–12, 111f
    - cuff selection for, 110, 111f
    - Doppler ultrasonography for, 111
    - oscillometric methods for, 111
    - photoplethysmographic methods for, 111
    - Ravi-Ricci return-to-flow principle with, 111, 112
  - maintenance of monitoring equipment for, 119–20
  - mean, 5
  - monitoring of, 105–12
  - normal values for, 106, 107t
  - systolic, 5, 6, 106, 107t
- Blood products, 130–32, 131f, 132f
  - cryoprecipitate, 130
  - fresh frozen plasma, 130
  - human immunoglobulin, 130–31, 132f
  - packed red blood cells, 130
  - whole blood, 130, 130f
- Blood typing, 131–32, 132f
  - cats, 132, 132f
- Blood urea nitrogen (BUN), 22, 249
- Blunt force trauma, 296
- BMD. *See* Basic minimum database
- BMG (butorphanol, midazolam, glycopyrrolate), 140f
- Body temperature
  - hyperthermia and, 99–100
  - hypothermia and, 98–99
  - monitoring of, 97–101
  - normal, 98
  - recovering patient's, 163
    - heating elements for, 163, 163f
- Brachycephalic breeds, 231–32, 231f, 232f
- Bradycardias, 216, 217t
- Bradycardia, sinus, 88–89
- Breathing, cardiopulmonary/cerebral resuscitation with, 175–76
- Breathing systems, 80–84, 81f, 82f
  - fresh gas flow rates, 83
  - low-flow circle, 83–84
  - nonbreathing, 81–83, 82f
  - rebreathing, 80–81, 81f
  - reservoir bag, 83
  - selection of, 84
  - semiclosed circle, 84
- Bronchi, 7
- Bronchioles, 7
- Buccal mucosal bleeding time, 23
- BUN. *See* Blood urea nitrogen
- BUN serum test, 22, 249
- Buprenorphine, 139
  - pediatric doses for, 270t
- Burn injuries, 295–96, 296f
- Butorphanol, 137t
  - drug combinations with, 140, 140t, 141t
  - equine preanesthetic sedative with, 363–64
  - geriatric doses for, 280t
- Butyrophenones, 136, 137t
  - cerebral blood flow with injectable, 222
- Calcium gluconate, cardiopulmonary/cerebral resuscitation with, 180t
- Capillaries, 8
- Capillary Refill Time (CRT), 101–2, 102f
- Capnograph, 113, 115f–118f, 119t
  - airway obstruction in, 117f
  - artifacts due to strong heart beat in, 117f
  - changes in, 119t
  - $\text{CO}_2$  rebreathing in, 117f
  - hyperventilation in, 116f
  - hypoventilation in, 115f
  - normal, 115f
  - spontaneous breaths during mechanical ventilation in, 116f
- Capnography, 112–13
- Capnometer, 113–14
- Carbon dioxide removal equipment, 75–76
  - APL valve, 76, 168
  - carbon dioxide absorber canister, 75, 168
  - one-way valves, 75–76
- Cardiac disease patients, 205–17
  - aortic stenosis with, 212, 214t

- atrial premature contractions with, 213
- atrial standstill with, 217
- AV block, 1st degree with, 216, 217t
- AV block, 2nd degree with, 216, 217t
- AV block, 3rd degree with, 216–17, 217t
- bradyarrhythmias with, 216, 217t
- classification of, 206–7, 207t
- dilated cardiomyopathy with, 208–9, 214t
- heart failure with, 207–8, 208f
- heartworm disease with, 212–13, 214t
- hypertrophic cardiomyopathy with, 209–10, 214t
- measures to optimize outcome for, 205–6
  - balanced anesthesia, 205–6
  - IV fluid support, 206
  - perioperative blood work evaluation, 206
  - premedications, 205
  - preoxygenation, 206
  - reduce stress, 205
  - ventilatory support, 206
- mitral regurgitation with, 210f
- mitral valve insufficiency with, 210, 210f, 214t
- patent ductus arteriosus with, 214t
- patent ductus arteriosus with, 210–11
- perianesthetic arrhythmias with, 213–16
- pulmonic stenosis with, 211–12, 214t
- subaortic stenosis with, 210f
- supraventricular arrhythmias with, 213, 217t
- ventricular premature contractions with, 213, 217t
- ventricular tachycardia with, 217t
- Cardiac output, 106, 106f
  - capnography for, 112
- Cardiogenic shock, fluid therapy contraindicated for, 130
- Cardiopulmonary arrest (CPA), 174–75
  - equipment for, 175–76
  - reasons for, 175
  - signs of, 174–75
- Cardiopulmonary/cerebral resuscitation (CPCR), 175–78
  - advance life support with, 178
  - airway management in, 175
  - breathing in, 175–76
  - circulation in, 176–78
  - complications with, 183–84
  - defibrillation with, 181–82
  - drugs used with, 178–79, 180t
    - atipamezole, 180t
    - atropine, 178–79, 180t
    - calcium gluconate, 180t
    - dobutamine, 180t
    - dopamine, 180t
    - epinephrine, 179, 180t
    - flumazenil, 180t
    - furosemide, 180t
    - glycopyrrolate, 178–79, 180t
    - lidocaine, 179, 180t
    - naloxone, 180t
    - sodium bicarbonate, 180t
    - vasopressin, 179, 180t
  - electrocardiography as monitor during, 181
  - fluid therapy with, 182
  - open chest, 178–84
  - prolonged life support with, 182–83
  - routes of drugs administration during, 179–81
    - central venous, 179
    - intracardiac, 181
    - intra lingual, 181
    - intraosseous, 179
    - intratracheal, 179–81
    - peripheral venous, 179
- Cardiovascular drugs, 16
- Cardiovascular system, 3–7
  - afterload with, 5
  - anatomy/physiology for, 3–4
  - anesthesia complication of, 172–74
  - anesthetic agents effects on, 215t
  - arrhythmias with, 5
  - atrioventricular node of, 3
  - blood pressure with, 5–7
  - cardiac cycle of, 4
  - contractility with, 5
  - determining heart rate from ECG, 4–7
  - electrical activity of, 4
    - AV conduction block, 4
    - electrocardiogram, 4
    - P-R interval, 4
    - P wave, 4
    - QRS complex, 4
    - Q-T interval, 4
    - T wave, 4
  - equine anesthesia and effects on, 360
  - preanesthetic workup exam for, 17–18, 25f
  - sino-atrial node of, 3
  - volume status with, 7
- Cataract removal, 202
- Catheterization, 49–55
  - arterial catheter for, 51, 51f, 108
  - blood pressure monitoring with, 108
  - care for, 54–55
  - catheter placement/stabilization for, 51–52, 52f, 53f
  - catheter size/type for, 49–50, 50f
    - multilumen, 49–50, 50f
    - through needle, 49
    - over needle, 49
  - choosing correct catheter for, 50
  - double lumen catheter for, 50–51, 50f
  - prepping site for, 52–54, 52f–54f
  - quadruple lumen catheter for, 50–51
  - single lumen central catheter for, 50, 54f
  - supplies for, 53–54

- triple lumen catheter for, 50–51
- troubleshooting, 54
- urinary, recovering patient with, 164–65
- vascular access ports for, 50
- venous catheter for, 51
- Cats
  - blood typing with, 132, 132f
  - intravenous potassium supplementation for, 129t
  - laryngospasm in, 64t
  - PRBC for, 133f
  - selecting appropriate tube for intubation of, 61
  - signs of acute pain in, 335f
- Caudal block, 375
- CBC. *See* Complete blood count
- Central venous pressure (CVP), 7
- Cerebral blood flow, 219–20
  - injectable anesthetics for, 221–23
- Cesarean section techniques, 283–90
  - anesthetic drug selection for, 284–88, 287t
    - induction agents, 285–86, 287t
    - maintenance agents, 286–88, 287t
    - preanesthetic agents, 284–85, 287t
  - anesthetic technique for, 288–89, 288f
  - resuscitation of newborn with, 289–90, 289f, 290f
- Chamber, inhalant induction procedures using, 143–44, 144f
- Chemistry profile, 22
- Chemotherapy drugs, 16
- Chronic pain, 326
- Cisatracurium, cerebral blood flow with injectable, 222–23
- Coagulation profile, 22
- Colloids, 124
- Complete blood count (CBC), 22
- Compliance, 189
- Complications, 167–84
  - cardiopulmonary arrest, 174–75
    - equipment for, 175–76
    - reasons for, 175
    - signs of, 174–75
  - cardiopulmonary/cerebral resuscitation, 183–84
    - glucose, 184
    - hyperthermia, 183–84
  - cardiovascular, 172–74
    - arrhythmias, 173
    - hypertension, 173
    - hypotension, 172
    - tachycardia, 173
    - ventricular fibrillation, 173–74
    - ventricular premature complexes, 173–74
    - ventricular tachycardia, 173–74
  - equipment, 168–69
    - APL valve complications, 168
    - carbon dioxide absorber exhaustion, 168
    - endotracheal tube complications, 67, 68t, 168
    - vaporizer complications, 168
  - ferrets, rodents, and rabbits with, 322
  - human error as cause of, 167
  - physiologic, 169–72
    - airway obstruction, 170–71
    - apnea, 170
    - aspiration, 169–70
    - excitation, 169
    - hyperventilation, 172
    - hypoventilation, 171
    - hypoxemia, 172
    - hypoxia, 172
    - laryngospasm, 171
    - prolonged recovery from anesthesia, 184
- Conjunctival flap, 202
  - positioning for, 203f
- Constant rate infusion (CRI), 33
- Contractility, 5
- Controlled substances, record keeping for, 37–39, 39f
- Controlled ventilation, 189
- Corneal reflex, 101, 101f
- Cornual nerve block, 374–75, 375f
- COX inhibition. *See* Cyclooxygenase inhibition
- CPA. *See* Cardiopulmonary arrest
- CPCR. *See* Cardiopulmonary/cerebral resuscitation
- Creatinine serum test, 22, 249
- CRI. *See* Constant rate infusion
- CRT. *See* Capillary Refill Time
- Cryoprecipitate, 130
- Crystalloids, 124
- Cushing reflex, 220–21
- Cushing's disease. *See* Hyperadrenocorticism
- CVP. *See* Central venous pressure
- Cyclohexamines, induction with, 145–46
- Cyclooxygenase inhibition (COX inhibition), renal disease anesthesia with, 254, 254t
- DABP. *See* Direct arterial blood pressure monitoring
- DACVA. *See* Diplomates of the American College of Veterinary Anesthesiologists
- Dead space ventilation, 9, 10f
- Defibrillation, cardiopulmonary/cerebral resuscitation with, 181–82
- Dehydration
  - clinical signs for, 126t
  - replacement requirement calculation for, 126f
- Demerol. *See* Meperidine
- Desaturation, 10, 233–34
- Desflurane, 158
  - inhalant anesthetics for ICP with, 223
  - minimum alveolar concentration of, 154t
  - vaporization pressure of, 155t
- Detomidine, equine preanesthetic sedative with, 362
- Dexmedetomidine. *See* Medetomidine

- Dextran, 125
- Diabetes mellitus, 239–40
- Diagnostics imaging, 24
  - radiography, 24
  - ultrasound, 24
- Diastolic blood pressure, 5, 106, 107t
- Diazepam (Valium), 136–37, 137t
  - cerebral blood flow with injectable, 222
  - equine preanesthetic sedative with, 363
  - geriatric doses for, 280t
  - induction with, 144–45, 147t, 149, 150t
  - liver disease pharmacology with, 260
- Dilated cardiomyopathy, 208–9, 214t
- Diplomates of the American College of Veterinary Anesthesiologists (DACVA), monitoring guidelines from, 85
- Diprivan. *See* Propofol
- Direct arterial blood pressure monitoring (DABP), 107–10, 109f
  - arterial catheter used for, 108
  - selecting catheter site for, 108
  - troubleshooting, 109–10
    - inaccurate readings, 110
    - sudden change in pressure, 110
    - waveform amplification, 110
    - waveform dampening/loss, 109–10
    - waveform not visible, 110
  - waveform interpretation for, 108, 109f
- Dissociative drugs, 138–39
  - cardiovascular effects from, 215t
  - liver disease pharmacology with, 260–61
- Dobutamine, cardiopulmonary/cerebral resuscitation with, 180t
- Dogs
  - blood typing with, 132, 132f
  - intravenous potassium supplementation for, 129t
  - larynx of, 64f
  - PRBC for, 133f
  - selecting appropriate tube for intubation of, 61
  - signs of acute pain in, 335f
- Dopamine, cardiopulmonary/cerebral resuscitation with, 180t
- Doppler ultrasonography, 111
- Dorsal horn
  - anatomy of, 328–29, 329f
  - neurochemistry of, 329–30
- Dose calculation, 30–31, 31t
- Drug calculation, 31–32
- ECG. *See* Electrocardiogram
- Elastic recoil, 8
- Electrocardiogram (ECG), 4, 24
  - applications for monitoring of, 86
  - arrhythmia in, 88
  - atrial fibrillation in, 91
  - atrial fibrillation premature complex in, 91
  - atrioventricular block in, 89–90, 89f
  - cardiopulmonary/cerebral resuscitation monitored with, 181
  - determining heart rate from, 4–7
  - hyperkalemia indicated by, 129
  - inaccurate data with, 87
  - interpreting data from, 87
  - monitoring information from, 86
    - P wave, 86
    - QRS complex, 86
    - T wave, 86, 87f
  - monitoring process for, 86–87
  - monitoring with, 86–91
  - physiology with, 86
  - sinus bradycardia in, 88–89
  - sinus tachycardia in, 88, 88f
  - ventricular fibrillation in, 91
  - ventricular premature contraction in, 90
  - ventricular tachycardia in, 90–91, 90f
- Electrolyte abnormalities, 127–30
  - hypochloremia/hyperchloremia, 127
  - hypokalemia/hyperkalemia, 128–30, 129t
  - hyponatremia/hyponatremia, 127–28, 128f
- Electroretinogram (ERG), anesthesia for, 201
- Emergencies, 167–84. *See also* Complications; Trauma patients
  - cardiopulmonary arrest, 174–75
    - equipment for, 175–76
    - reasons for, 175
    - signs of, 174–75
  - cardiopulmonary/cerebral resuscitation, 175–78
    - advance life support with, 178
    - airway management in, 175
    - breathing in, 175–76
    - circulation in, 176–78
    - complications with, 183–84
    - defibrillation with, 181–82
    - drugs used with, 178–79, 180t
    - electrocardiography as monitor during, 181
    - fluid therapy with, 182
    - open chest, 178–84
    - prolonged life support with, 182–83
    - routes of drugs administration during, 179–81
  - crash protocols, 174–75
    - equipment for, 174–75
  - ferrets, rodents, and rabbits in, 322
  - nontrauma, 301–10
    - foreign bodies/obstructions, 305–7
    - gastric dilatation-volvulus, 303–5, 304f
    - intervertebral disk disease, 307–9, 308f, 309f
    - pyometra, 310
    - shock, 301–3
    - urethral obstruction, 309–10
- Endocrine diseases, 239–43
  - diabetes mellitus, 239–40

- hyperadrenocorticism (Cushing's disease), 241–42, 241f
- hyperthyroidism, 242–43
- hypoadrenocorticism (Addison's disease), 242
- hypothyroidism, 243
- insulinoma, 240
- Endocrine system
  - preanesthetic workup exam for, 20, 25f
  - testing for, 24
- Endotracheal tubes, 57–70
  - cleaning and sterilization of, 67–70
  - complications with, 67, 68t, 168
  - design for, 59–60, 60f
  - extubation with, 66–67, 67t
    - patient recovery and, 165–66
    - three-way stopcock with, 66, 67t
  - facemask v., 58t
  - intubation with, 63–66, 63f
    - assistant holds head for, 63, 63f
    - cuff inflation guidelines with, 65t
    - guidelines for success with, 63t
    - laryngospasm with, 64t
    - placement confirmation with, 66t
    - tube tie with, 66t
  - proper/improper lengths of, 114f
  - selecting appropriate tube for, 60–61
  - special, 58–59, 59f
  - storage of, 67–70, 69f
  - supplies for intubation with, 61–63
    - laryngoscopes, 61–62, 62f
    - stylet and guide tubes, 62–63, 62f
  - types of, 57–58, 58f
- End-tidal carbon dioxide (ETCO<sub>2</sub>), 92
  - anatomic dead space with, 113
  - capnograph for monitoring of, 113, 115f–118f, 119t
    - airway obstruction in, 117f
    - artifacts due to strong heart beat in, 117f
    - CO<sub>2</sub> rebreathing in, 117f
    - hyperventilation in, 116f
    - hypoventilation in, 115f
    - normal, 115f
    - spontaneous breaths during mechanical ventilation in, 116f
  - capnometer for monitoring of, 113–14
  - causes for change in, 119t
  - equine anesthesia maintenance with, 369
  - mainstream (nondiverting) monitor for, 114
  - maintenance of monitoring equipment for, 119–20
  - mechanical dead space with, 113
  - monitoring of, 113–20
  - monitor types for, 113–14
  - primary methods for monitoring of, 113
    - infrared light absorption, 113
    - mass spectroscopy, 113
  - sidestream (diverting) monitor for, 114–19
- Enucleation, 202
- Epidural block, 377–78
- Epinephrine, cardiopulmonary/cerebral resuscitation with, 179, 180t
- Equine anesthesia, 357–71
  - cardiovascular effects with drugs for, 360
  - different circumstances with drugs for, 359–60
  - dose range with drugs for, 359
  - five phases of, 360
    - induction phase, 360
    - maintenance phase, 360
    - postanesthetic phase, 360
    - preanesthetic phase, 360
    - recovery phase, 360
  - four pillars of, 359–60
    - assessment, 358, 358f
    - familiarity, 358–59
    - planning, 359
    - readiness, 358, 359f
  - individual differences with drugs for, 359
  - induction phase of, 364–65
    - guaifenesin, 364
    - ketamine, 364–65
    - tolazoline-zolazepam, 365
  - maintenance phase of, 365–70
    - balanced anesthesia in, 366
    - end-tidal CO<sub>2</sub> in, 369
    - hypotension treatment for, 367–68
    - inhalant anesthetics for, 365
    - monitoring in, 366–67
    - padding/positioning in, 366, 366f
    - pulse oximetry in, 369
    - respiration in, 368–69
    - TIVA in, 365–66
    - ventilation in, 369
  - postanesthetic phase in, 371
  - preanesthetic phase of, 360–64
    - emptying GI tract in, 361
    - laboratory results in, 361
    - patient physical examination in, 360–61
    - sedative in, 360–64
  - preanesthetic sedative for, 362–64
    - acepromazine, 363
    - atropine, 363
    - butorphanol, 363–64
    - detomidine, 362
    - diazepam, 363
    - medetomidine (Dexmedetomidine), 363
    - morphine, 364
    - xylazine, 362
  - recovery phase of, 370–71
    - anesthetic agent elimination in, 370
    - antagonists in, 370–71
    - oxygenation in, 371
    - patent airway in, 371
    - sedation in, 370

- Equipment. *See* Anesthesia equipment
- ERG. *See* Electroretinogram
- Esophageal stethoscope, 102–3, 103f
- ETCO<sub>2</sub>. *See* End-tidal carbon dioxide
- Etomidate (Amidate)
- cardiovascular effects from, 215t
  - cerebral blood flow with injectable, 222
  - induction with, 147, 147t, 150t
  - liver disease pharmacology with, 260
  - pediatric patients induction with, 270t, 271
- Excel worksheet
- drug calculation with, 31–32
  - fluid calculation with, 32, 32t
- Excitation, anesthesia complicated by, 169
- Extraocular procedures, anesthesia for, 201
- Extubation, 66–67, 67t
- patient recovery and, 165–66
  - three-way stopcock with, 66, 67t
- Fentanyl, 137t, 139
- induction for respiratory-challenged patients with, 231t
  - induction with, 149, 150t
- Ferrets, 313–17
- anesthesia induction, care and support for, 314–15
  - anesthesia preparation for, 313–14
  - anesthesia recovery with, 316
  - emergency considerations for, 322
  - fluid therapy plan for, 316
  - monitoring during anesthesia for, 316
- FFP. *See* Fresh frozen plasma
- Fluid calculation, 32, 32t
- Fluid drip rates calculation, 31–32
- Fluids
- classifications of, 124–25
    - albumin, 124–25
    - colloids, 124
    - crystalloids, 124
    - dextran, 125
    - hetastarch, 125
  - transcellular, 123
- Fluid therapy, 123–34
- cardiogenic shock with, 130
  - cardiopulmonary/cerebral resuscitation with, 182
  - electrolyte abnormalities requiring, 127–30
    - hypochloremia/hyperchloremia, 127
    - hypokalemia/hyperkalemia, 128–30, 129t
    - hyponatremia/hypernatremia, 127–28, 128f
  - ferrets, plan for, 316
  - hydration deficit replacement requirement
    - calculation for, 126f
  - hypovolemic shock requiring, 129
  - long-term, 126
  - maintenance, 125–26
  - obstructive shock with, 130
  - replacement, 126–27, 126f, 126t
  - resuscitation, 127
  - types of, 125–27
- Flumazenil
- cardiopulmonary/cerebral resuscitation with, 180t
  - geriatric doses for, 280t
  - pediatric doses for, 270t
- Foreign bodies/obstructions, 305–7
- FRC. *See* Functional residual capacity
- Fresh frozen plasma (FFP), 130
- Functional residual capacity (FRC), 9, 189
- Furosemide, cardiopulmonary/cerebral resuscitation with, 180t
- Gabapentin, pain management with, 352
- Gag reflex, 160
- Gastric dilatation-volvulus (GDV), 303–5, 304f
- Gastrointestinal system, preanesthetic workup exam for, 19, 25f
- GDV. *See* Gastric dilatation-volvulus
- Geriatric patients, 275–81
- induction for, 278–79, 280t
    - alfaxalone, 279, 280t
    - etomidate, 278–79, 280t
    - ketamine, 279, 280t
    - propofol, 278, 280t
  - maintenance for, 279
  - monitoring for, 279–81, 280f
  - physiology of, 275–76
  - preanesthesia preparation for, 276
  - premedication for, 276–78
    - acepromazine, 277–78, 280t
    - alpha-2 agonists, 278
    - anticholinergics, 278, 280t
    - benzodiazepine, 277, 280t
    - opioids, 277, 280t
  - recovery for, 281
- GFR. *See* Glomerular filtration rate
- Glomerular filtration rate (GFR), 249
- Glycopyrrolate, 136, 137t
- cardiopulmonary/cerebral resuscitation with, 178–79, 180t
  - drug combinations with, 140, 140t, 141t
  - geriatric doses for, 280t
  - pediatric doses for, 270t
- Guaiifenesin, equine induction phase with, 364
- HAG (hydromorphone, acepromazine, glycopyrrolate), 141
- Halothane, 156–57
- cardiovascular effects from, 215t
  - inhalant anesthetics for ICP with, 223
  - minimum alveolar concentration of, 154t
  - vaporization pressure of, 155t
- HCO<sub>3</sub>. *See* Bicarbonate level



- Head trauma, 219–24  
MRI of, 220f
- Heart. *See also* Cardiovascular system  
anatomy/physiology of, 3–4  
atrioventricular node of, 3  
cardiac cycle of, 4  
ECG—determining rate of, 4–7  
mitral valve, 4  
murmurs, 4  
normal blood flow through, 208f  
sino-atrial node of, 3  
tricuspid valve, 4  
volume status with, 7
- Heart failure, 207–8, 208f
- Heart rate, 106, 106f
- Heartworm disease, 212–13, 214t
- Hepatic system, preanesthetic workup exam for, 19, 25f
- Hetastarch, 125
- Hoffman elimination, 199
- Human immunoglobulin (IGg), 130–31, 132f
- Hyaluronic acid, 353
- Hydromorphone, 137t, 139  
drug combinations with, 140t, 141, 141t  
induction for respiratory-challenged patients with, 231t  
induction with, 149, 150t
- Hyperadrenocorticism (Cushing’s disease), 241–42, 241f
- Hypercarbia, 10
- Hypertension, anesthesia complicated by, 173
- Hyperthermia, 99–100  
causes of, 100  
malignant, 100  
treatment of, 100
- Hyperthyroidism, 242–43
- Hypertrophic cardiomyopathy, 209–10, 214t
- Hyperventilation, 188  
anesthesia complicated by, 172  
capnograph showing, 116f
- Hypoadrenocorticism (Addison’s disease), 242
- Hypocapnia, 188
- Hypochloremia/hyperchloremia, 127  
cause of, 127  
treatment of, 128, 128f
- Hypokalemia/hyperkalemia, 128–30, 129t  
clinical signs of, 128–29  
ECG changes indicating, 129  
treatment of, 129, 129t
- Hyponatremia/hypernatremia, 127–28, 128f  
clinical signs of, 127–28  
fluid rate calculation for correction of, 128f  
treatment of, 128, 128f
- Hypotension  
anesthesia complicated by, 172  
treatment for equine with, 367–68
- Hypothermia, 98–99  
active patient warming for, 99  
monitoring body temperature with, 98  
prevention of, 98–99
- Hypothyroidism, 243
- Hypoventilation, 188–89  
anesthesia complicated by, 171  
capnograph showing, 115f
- Hypovolemic shock, 129
- Hypoxemia, 10, 189  
anesthesia complicated by, 172
- Hypoxia, anesthesia complicated by, 172
- ICP. *See* Intracranial pressure
- IGg. *See* Human immunoglobulin
- Induction drugs, 143–50  
inhalant induction procedures for, 143–44, 144f  
chamber, 143–44, 144f  
mask, 143, 144f  
injectable induction agents, 144–47, 147t  
acepromazine, 149  
barbiturates, 147–49  
benzodiazepines, 144–45  
cyclohexamines, 145–46  
diazepam, 144–45, 147t, 149, 150t  
etomidate, 147, 147t, 150t  
fentanyl, 149, 150t  
hydromorphone, 149, 150t  
ketamine (ketaset, vetalar, ketalean), 145, 147t, 150t  
meperidine, 149  
methylated oxybarbiturate (methohexital), 148–49  
midazolam (versed), 145, 147t, 149, 150t  
morphine, 149  
neuroleptanalgesia, 149–50  
opioids, 149  
oxymorphone, 149, 150t  
propofol, 146–47, 147t, 150t  
thiobarbiturate (thiopental), 148–49  
tiletamine (Telazol), 145–46, 147t, 150t  
zolazepam, 145, 147t, 150t
- Infrared light absorption, 113
- Inhalant anesthetics, 153–58  
characteristics of ideal, 153–54  
desflurane, 158  
minimum alveolar concentration of, 154t  
vaporization pressure of, 155t  
halothane, 156–57  
minimum alveolar concentration of, 154t  
vaporization pressure of, 155t  
history, 153  
induction procedures with, 143–44, 144f

- isoflurane, 157
  - minimum alveolar concentration of, 154t
  - vaporization pressure of, 155t
- mechanism of action for, 154
- minimum alveolar concentration for, 154–55, 154t
  - desflurane, 154t
  - halothane, 154t
  - isoflurane, 154t
  - nitrous oxide, 154t
  - sevoflurane, 154t
- nitrous oxide, 156
  - minimum alveolar concentration of, 156
- pharmacokinetics of, 154
- sevoflurane, 157–58, 157f
  - minimum alveolar concentration of, 154t
  - vaporization pressure of, 155t
- solubility coefficient of, 155, 155t
- vaporization pressure of, 155, 155t
  - desflurane, 155t
  - halothane, 155t
  - isoflurane, 155t
  - sevoflurane, 155t
- Inspiratory to Expiratory Ratio (I:E ratio), 190, 190f, 191
- Insulin, 17
- Insulinoma, 240
- Integument system, preanesthetic workup exam for, 19–20, 25f
- Intercranial pressure (ICP), 219–24
  - anesthetic agents effect on, 221
  - anesthetics management for, 223–24
  - autoregulation with, 219–20
  - cerebral blood flow with, 219–20
    - CO<sub>2</sub> and O<sub>2</sub>'s effect on, 221
  - Cushing reflex with, 220–21
  - factors causing increase in, 221
  - inhalant anesthetics for, 223
    - desflurane, 223
    - halothane, 223
    - isoflurane, 223
    - nitrous oxide, 223
    - sevoflurane, 223
  - injectable anesthetics for, 221–23
    - barbiturates, 222
    - benzodiazepine, 222
    - butyrophenone, 222
    - cisatracurium, 222–23
    - diazepam, 222
    - etomidate, 222
    - ketamine, 222
    - lidocaine, 222
    - midazolam, 222
    - phenothiazine, 222
    - propofol, 222
    - vecuronium, 222–23
  - recovery for anesthetics used for, 224
- Intermittent positive pressure ventilation, 188
- Interstitial edema, 123
- Interstitium, 123
- Intervertebral disk disease (IVDD), 307–9, 308f, 309f
- Intracellular compartment, 123
- Intraocular pressure (IP), determinants of, 195–96, 196t
- Intraocular procedures
  - anesthesia for, 202
  - positioning for, 202–3, 203f
- Intravenous access, 49–55
  - arterial catheter for, 51, 51f
  - cardiac disease patient outcome with, 206
  - care for, 54–55
  - catheter placement/stabilization for, 51–52, 52f, 53f
  - catheter size/type for, 49–50, 50f
    - multilumen, 49–50, 50f
    - through needle, 49
    - over needle, 49
  - choosing correct catheter for, 50
  - double lumen catheter for, 50–51, 50f
  - prepping site for, 52–54, 52f–54f
  - quadruple lumen catheter for, 50–51
  - single lumen central catheter for, 50, 54f
  - supplies for, 53–54
  - triple lumen catheter for, 50–51
  - troubleshooting, 54
  - vascular access ports for, 50
  - venous catheter for, 51
- Intubation, 63–66, 63f
  - assistant holds head for, 63, 63f
  - cuff inflation guidelines with, 65t
  - guidelines for success with, 63t
  - laryngospasm with, 64t
  - placement confirmation with, 66t
  - tube tie with, 66t
- IP. *See* Intraocular pressure
- Isoflurane, 157
  - cardiovascular effects from, 215t
  - inhalant anesthetics for ICP with, 223
  - minimum alveolar concentration of, 154t
  - vaporization pressure of, 155t
- IVDD. *See* Intervertebral disk disease
- IV fluids. *See also* Intravenous access
  - administering agent by adding to, 33
- Jaw tone, 101, 102f
- JGA. *See* Juxtaglomerular apparatus
- Juxtaglomerular apparatus (JGA), 246–47, 248f
- KBAG (ketamine + BAG), 141, 141f
- Ketalean. *See* Ketamine
- Ketamine (Ketaset, Vetalar, Ketalean), 137t, 138–39
  - cerebral blood flow with injectable, 222
  - drug combinations with, 141, 141t
  - equine induction phase with, 364–65

- induction for respiratory-challenged patients with, 230t, 231t
- induction with, 145, 147t, 150t
- IV fluids with administration of, 33
- pediatric patients induction with, 270, 270t
- Ketaset. *See* Ketamine
- KHAG (ketamine, hydromorphone, acepromazine, glycopyrrolate), 141, 141f
- Kitty Magic, 141–42, 141t
  
- Laryngoscopes, 61–62, 62f
- Laryngospasm, 64t
  - anesthesia complicated by, 171
- Lasix, percent solution calculations, 30
- Lidocaine
  - cardiopulmonary/cerebral resuscitation with, 179, 180t
  - cardiovascular effects from, 215t
  - cerebral blood flow with injectable, 222
  - induction for respiratory-challenged patients with, 230t, 231t
  - IV fluids with administration of, 33
  - liver disease pharmacology with, 261
  - percent solution calculations, 30
- Liver, anatomy of, 257, 258f
- Liver disease, 257–64
  - blood work to consider before anesthesia for, 257–58, 259t
  - conditions that affect liver, 261–64, 262f, 263f
  - drug protocol design for, 264
  - pharmacology for, 258–61
    - alpha-2 agonists, 259–60
    - barbiturates, 260
    - benzodiazepine, 259–60
    - diazepam, 260
    - dissociative drugs, 260–61
    - etomidate, 260
    - lidocaine, 261
    - nonsteroidal antiinflammatory drugs, 261
    - opioids, 260
    - phenothiazine, 259
    - propofol, 260
- Low-flow circle system, 83–84
  
- MAC. *See* Minimum alveolar concentration
- Mainstream (nondiverting) monitor, 114
- MAP. *See* Mean arterial pressure
- Mapleson system, 81
- Mask, inhalant induction procedures using, 143, 144f
- Mass spectroscopy, 113
- Mathematics, 29–34
  - administering agent by adding to IV fluids, 33
  - agent dose calculation, 30–31, 31t
  - agent strength percent solution calculations, 30
  - constant rate infusion, 33
  - Excel worksheet for drug calculation, 31–32
  - Excel worksheet for fluid calculation, 32, 32t
  - fluid drip rates calculation, 31–32
  - metric system, 29–30, 29t, 30t
  - percentages, 30
- Mean arterial pressure (MAP), 5, 6
  - equation for, 106
- Mechanical dead space, 10, 113
- Medetomidine (Dexmedetomidine), 137t, 138
  - equine preanesthetic sedative with, 363
- Meperidine (Demerol), induction with, 149
- Methadone, 137t, 139
  - pediatric doses for, 270t
- Methohexital. *See* Methylated oxybarbiturate
- Methylated oxybarbiturate (Methohexital), induction with, 148–49
- Metric system, 29–30, 29t, 30t
- Midazolam (Versed), 136–37, 137t
  - cerebral blood flow with injectable, 222
  - drug combinations with, 140t
  - geriatric doses for, 280t
  - induction with, 145, 147t, 149, 150t
  - pediatric doses for, 270t
- Minimum alveolar concentration (MAC), 154–55, 154t
  - desflurane, 154t
  - halothane, 154t
  - isoflurane, 154t
  - nitrous oxide, 154t
  - sevoflurane, 154t
- Minute volume, 9
- Mitral regurgitation, 210f
- Mitral valve, 4
- Mitral valve insufficiency, 210, 210f, 214t
- MM. *See* Mucus membrane color
- Modified Jackson Rees system, 82
- Monitoring, 85–120
  - anesthesia of ferrets, 316
  - anesthetic depth, 101–3, 101f–103f
    - Capillary Refill Time in, 101–2, 102f
    - corneal reflex in, 101, 101f
    - esophageal stethoscope in, 102–3, 103f
    - jaw tone in, 101, 102f
    - mucus membrane color in, 101
    - palpation of arteries in, 102, 102f
    - palpebral reflex in, 101
    - position of eye in, 101
    - swallowing reflex in, 101
    - withdrawal reflex in, 101, 101f
  - ASA physical status scale, 85
  - blood gas analysis, 91–93
    - components of, 92–93
    - errors in sampling with, 93
    - physiology with, 92
    - sample collection for, 93
  - blood pressure, 105–12
    - direct (invasive) monitoring of, 107–10, 109f
    - factors determining, 106, 106f

- indirect (noninvasive) monitoring of, 110–12, 111f
  - normal values for, 106, 107t
- body temperature, 97–101
  - hyperthermia and, 99–100
  - hypothermia and, 98–99
  - normal, 98
- capnography for, 112–13
- DACVA guidelines for, 85
- electrocardiogram, 86–91
  - applications for monitoring of, 86
  - arrhythmia in, 88
  - atrial fibrillation in, 91
  - atrial fibrillation premature complex in, 91
  - atrioventricular block in, 89–90, 89f
  - cardiopulmonary/cerebral resuscitation with, 181
  - inaccurate data with, 87
  - interpreting data from, 87
  - monitoring information from, 86
  - monitoring process for, 86–87
  - physiology with, 86
  - sinus bradycardia in, 88–89
  - sinus tachycardia in, 88, 88f
  - ventricular fibrillation in, 91
  - ventricular premature contraction in, 90
  - ventricular tachycardia in, 90–91, 90f
- end-tidal carbon dioxide, 113–20
  - capnograph for, 113, 115f–118f, 119t
  - capnometer for, 113–14
  - causes for change in, 119t
  - mainstream (nondiverting) monitor for, 114
  - maintenance of monitoring equipment for, 119–20
  - monitor types for, 113–14
  - primary methods for, 113
  - sidestream (diverting) monitor for, 114–19
- equine anesthesia, 366–67
- hands-on, 101–3
- neuromuscular blockade, 200–201, 200f
- patient recovery, 162–63, 163f
- pediatric patients, 272–73, 273f
- pulse oximetry, 95–97
  - factors influencing accuracy of, 96
  - interpretation of data from, 97
  - patient assessment/treatment of decreased SpO<sub>2</sub> with, 97
  - physiology with, 95–96
  - types of, 96, 96f
  - working of, 95–96
- record grid for, 37
- Morphine, 137t, 139
  - drug combinations with, 140t, 141, 141t
  - equine preanesthetic sedative with, 364
  - induction for respiratory-challenged patients with, 230t
  - induction with, 149
  - IV fluids with administration of, 33
  - pediatric doses for, 270t
- Mucus membrane color (MM), 101
- Murmurs, 4
- Naloxone, 139
  - cardiopulmonary/cerebral resuscitation with, 180t
  - geriatric doses for, 280t
  - pediatric doses for, 270t
- Nerve stimulator, 200, 200f
- Nervous system, preanesthetic workup exam for, 19, 25f
- Neuroleptanalgesia, induction with, 149–50
- Neuromuscular blockade (NMB), 198–201
  - drugs specific for, 199–200
  - atracurium, 199
  - monitoring of, 200–201, 200f
    - nerve stimulator for, 200, 200f
  - neuromuscular junction with, 199
  - reversal of, 201
  - types of, 199
    - depolarizing, 199
    - nondepolarizing, 199
  - use with ophthalmic procedures of, 198–99
  - ventilation with, 200
- Neuropathic pain, 327
- Nitrous oxide, 156
  - inhalant anesthetics for ICP with, 223
  - minimum alveolar concentration of, 156
  - renal disease anesthesia with, 252, 253t
- NMB. *See* Neuromuscular blockade
- NMDA receptor antagonists, adaptive pain management with, 348–49
- Nonbreathing system, 81–83, 82f
  - Bain Coaxial system, 82, 82f
  - flow rates for, 84
  - high pressure alarm for, 82
  - Mapleson system, 81
  - Modified Jackson Rees system, 82
- Nonsteroidal antiinflammatory drugs (NSAID), 16
  - adaptive pain management with, 347
  - liver disease pharmacology with, 261
  - pain management with, 352
  - renal disease anesthesia with, 252–54, 253t
- Nontrauma emergency patients, 301–10
  - foreign bodies/obstructions, 305–7
  - gastric dilatation-volvulus, 303–5, 304f
  - intervertebral disk disease, 307–9, 308f, 309f
  - pyometra, 310
  - shock, 301–3
    - urethral obstruction, 309–10
- NSAID. *See* Nonsteroidal antiinflammatory drugs
- Numorphan. *See* Oxymorphone
- O\*BAG (Old dog BAG), 140, 140f
- Obstructive shock, 130

- OCR. *See* Oculocardiac reflex
- Ocular procedures  
  anesthesia for, 202  
  positioning for, 202–3, 203f  
  recovery from procedures for, 203
- Ocular trauma, 294
- Oculocardiac reflex (OCR), 196
- Ophthalmology patients, 195–203  
  anesthesia for electroretinogram with, 201  
  anesthesia for extraocular procedures for, 201  
  anesthesia for ocular/intraocular procedures for, 202  
  cataract removal, 202  
  conjunctival flap, 202  
  enucleation, 202  
  general considerations for, 195  
  induction/maintenance of anesthesia for, 197  
  intraocular pressure determinants with, 195–96, 196t  
  local blocks for, 198  
  local infiltration of anesthetic with, 198  
  retrobulbar block, 198  
  neuromuscular blockade for, 198–201  
  drugs specific for, 199–200  
  monitoring of, 200–201, 200f  
  neuromuscular junction with, 199  
  reversal of, 201  
  types of, 199  
  use with ophthalmic procedures of, 198–99  
  ventilation with, 200  
  oculocardiac reflex with, 196  
  positioning for procedures for, 202–3, 203f  
  premedication for, 196–97  
  recovery from procedures for, 203
- Opioids, 139–40  
  adaptive pain management with, 348, 349f, 349t  
  cardiovascular effects from, 215t  
  induction with, 149  
  liver disease pharmacology with, 260  
  pain management with, 352  
  pediatric patients premedication with, 268–69, 270t  
  renal disease anesthesia with, 251, 253t
- Organophosphates, 17
- Oscillometric methods, 111
- Oxygen delivery equipment, 71–73, 72f  
  compressed gas cylinder, 71  
  flowmeter, 72–73, 72f  
  oxygen concentrator, 71  
  regulator, 71, 72f  
  troubleshooting, 77
- Oxygen saturation (SaO<sub>2</sub>), 92–93
- Oxymorphone (Numorphan), 137t, 139  
  drug combinations with, 140t, 141, 141t  
  geriatric doses for, 280t  
  induction for respiratory-challenged patients with, 231t  
  induction with, 149, 150t  
  pediatric doses for, 270t
- Packed cell volume (PCV), 22
- Packed red blood cells (PRBC), 130  
  cat/dog, 133f
- PaCO<sub>2</sub>. *See* Partial pressure of carbon dioxide
- Pain, 325–55  
  adjunct therapies for, 353–54  
  acupuncture, 353–54  
  therapeutic laser, 354, 354f  
  weight loss, 354  
  assessment of, 333–43  
  age differences for, 336  
  behavioral signs for, 334–36, 337f  
  breed differences for, 335  
  chronic pain in, 342–43, 342f  
  frequency of, 338–39  
  general acute, 337–39, 337f  
  individual characteristics for, 336  
  painful conditions/procedures in, 339  
  pain scoring systems for, 339–42, 340, 341f  
  role of technician in, 334  
  species differences for, 334–35, 335f  
  classification of, 325–27, 346  
  acute v. chronic, 326, 346  
  adaptive v. maladaptive, 346  
  physiologic v. pathologic, 325–26  
  referred v. neuropathic, 327  
  somatic v. visceral, 326–27  
  gate control theory of, 330–31, 330f  
  glucosamine-containing supplements for, 353  
  hyaluronic acid for, 353  
  joint/cartilage structure modifiers for, 353  
  management of adaptive, 347–50  
  alpha-2 agonists, 347–50  
  local anesthetics, 349–50, 350f  
  NMDA receptor antagonists, 348–49  
  nonsteroidal antiinflammatory drugs, 347  
  opioids, 348, 349f, 349t  
  tramadol, 348  
  management of maladaptive, 350–53  
  management strategies for, 345–55  
  central neuronal hypersensitization in, 345–46  
  designing optimal, 345–46, 346t  
  multimodal analgesia for, 345, 346t  
  preemptive analgesia in, 346  
  neuroendocrine signs of, 336–37  
  pathways, 329–30, 327f  
  afferent nerve fibers, 327–28, 328t  
  ascending spinal tracts with, 330  
  dorsal horn neurochemistry with, 329–30  
  spinal cord dorsal horn anatomy with, 328–29, 329f

- pharmaceuticals for, 352–53
  - acetaminophen, 352
  - amantadine, 352
  - gabapentin, 352
  - nonsteroidal antiinflammatory drugs, 352
  - opioids, 352
  - tramadol, 352–53
- physical therapy for, 354–55, 355f
- physiologic signs of, 336–37
- polysulfated glycosaminoglycans for, 353
- postsurgical, 351f
- regenerative stem cell therapy for, 355
- Palpation of arteries, 102, 102f
- Palpebral reflex, 101
- PaO<sub>2</sub>. *See* Partial pressure of oxygen
- Partial pressure of carbon dioxide (PaCO<sub>2</sub>), 92
- Partial pressure of oxygen (PaO<sub>2</sub>), 92
- Patent ductus arteriosus (PDA), 210–11, 214t
- Pathologic pain, 325–26
- Patient recovery, 159–66
  - analgesia for, 165
  - anesthesia recovery with, 224
  - bandage placement with, 164
  - bedding for, 166
  - body temperature with, 163
    - heating elements for, 163, 163f
  - endotracheal tube extubation for, 165–66
  - ferrets in, 316
  - geriatric patients in, 281
  - monitoring patient during, 162–63, 163f
  - nasal oxygen placement with, 163–64
  - procedures overview for, 159–61
  - prolonged recovery from anesthesia, 184
  - rabbits in, 319
  - recovery room with, 161–62, 162f
  - regurgitation during, 165
  - removing monitoring equipment with, 162
  - rodents in, 319
  - tracheostomy patient, 164
  - tranquilization for, 165
  - transferring recovering patient with, 162
  - urinary catheter management in, 164–65
- PCV. *See* Packed cell volume
- PDA. *See* Patent ductus arteriosus
- Peak Inspiratory Pressure (PIP), 189–90
- Pediatric patients, 267–73
  - induction for, 269–72, 270t
    - alfaxalone, 270t, 271
    - etomidate, 270t, 271
    - inhalation agents for, 271, 271f
    - ketamine, 270, 270t
    - propofol, 269, 270t
  - maintenance for, 271–72
  - monitoring for, 272–73, 273f
  - physiology with, 267–68
  - postanesthesia for, 273
    - preanesthesia preparation for, 268, 268f
    - premedication for, 268–69, 270t
      - acepromazine, 269, 270t
      - alpha-2 agonists, 269
      - anticholinergics, 269, 270t
      - benzodiazepine, 269, 270t
      - opioids, 268–69, 270t
    - thermoregulation for, 272
- PEEP. *See* Positive end expiratory pressure
- Percentage calculations, 30
- Percent solution calculations
  - agent strength, 30
  - preparing, 32
- Perfusion pressure, renal system, 246
- Perianesthetic arrhythmias, 213–16
- pH, 92
- Phenobarbital, 16–17
- Phenothiazines, 136
  - cardiovascular effects from, 215t
  - cerebral blood flow with injectable, 222
  - liver disease pharmacology with, 259
  - renal disease anesthesia with, 251, 253t
- Photoplethysmographic methods, 111
- Physical therapy, pain management with, 356–57, 355f
- Physiologic pain, 325–26
- PIP. *See* Peak Inspiratory Pressure
- Platelet count, 23
- Polysulfated glycosaminoglycans (PSGAG), 353
- Position of eye, 101
- Positive end expiratory pressure (PEEP), 9, 190
- Positive pressure ventilation (PPV), 9
- PPV. *See* Positive pressure ventilation
- PRBC. *See* Packed red blood cells
- Preanesthetic preparation, 41–48
  - check equipment/monitor setup in, 41
  - check vaporizer in, 42
  - crash cart made available in, 44
  - endotracheal tube chosen for, 43
  - IV supplies preparation, 43–45
  - premedication/induction agent labeling in, 43
  - preparation for induction in, 43, 43f
  - pressure check anesthesia machine in, 41, 42f
  - squeeze out rebreathing bag in, 41, 42f
  - surgery room setup in, 45
  - OR table setup in, 46–47, 46f
  - thermoregulatory support preparation in, 46
- Preanesthetic workup, 13–26, 14f
  - ASA status, 20–21, 21f
  - current medication knowledge in, 16–17
    - adjunctive analgesics drugs, 16
    - analgesics, 16
    - antibiotics, 16
    - cardiovascular drugs, 16
    - chemotherapy drugs, 16
    - insulin, 17

- nonsteroidal antiinflammatory drugs, 16
  - organophosphates, 17
  - phenobarbital, 16–17
- diagnostics, 21–22
  - ALT, AST, and alkaline phosphatase serum tests, 22
  - arterial blood gases, 24
  - basic minimum database, 21
  - blood glucose, 22
  - Buccal mucosal bleeding time, 23
  - BUN serum test, 22, 249
  - coagulation profile, 22
  - complete blood count, 22
  - creatinine serum test, 22, 249
  - electrocardiogram, 24
  - endocrine testing, 24
  - full chemistry profile, 22
  - full urinalysis, 23–24
  - packed cell volume, 22
  - platelet count, 23
  - thrombocytopenic count, 23
  - total plasma protein, 22
  - urine specific gravity, 22
- diagnostics imaging, 24
  - radiography, 24
  - ultrasound, 24
- flow chart for, 14f
- influencing factors with, 13–16
- physical exam in, 17–20
  - cardiovascular system, 17–18, 25f
  - endocrine system, 20, 25f
  - gastrointestinal system, 19, 25f
  - hepatic system, 19, 25f
  - integument system, 19–20, 25f
  - nervous system, 19, 25f
  - overall body condition, 20, 20f
  - renal system, 18, 25f
  - respiratory system, 18, 25f
- SOAP for, 24, 26f
- Preemptive analgesia, 348
- Pregnancy. *See also* Cesarean section techniques
  - physiological alterations in, 283–84
- Premature ventricular contraction. *See* Ventricular premature contraction
- Premedication drugs, 135–42
  - acepromazine, 136, 137t
  - alpha-2 agonists, 137–38
  - anticholinergics, 136
  - atropine, 136, 137t
  - benzodiazepines, 136–37
  - buprenorphine, 139
  - butorphanol, 137t
  - butyrophenones, 136, 137t
  - combination does, 140–42
    - BAG (butorphanol, acepromazine, glycopyrrolate), 140–41, 140f
    - BMG (butorphanol, midazolam, glycopyrrolate), 140f
    - HAG, 141
    - KBAG, 141, 141f
    - KHAG, 141, 141f
    - Kitty Magic, 141–42
    - O'BAG, 140, 140f
  - dexmedetomidine, 137t, 138
  - diazepam, 136–37, 137t
  - dissociative drugs, 138–39
  - fentanyl, 137t, 139
  - glycopyrrolate, 136, 137t
  - hydromorphone, 137t, 139
  - ketamine, 137t, 138–39
  - medetomidine, 137t, 138
  - methadone, 137t, 139
  - midazolam, 136–37, 137t
  - morphine, 137t, 139
  - naloxone, 139
  - opioids, 139–40
  - oxymorphone, 137t, 139
  - phenothiazines, 136
  - protocol for, 136
  - tiletamine, 138
  - tiletamine (Telazol), 137
  - tranquilizers, 136–37
  - xylazine, 137t, 138
  - zolazepam, 136–37
- Preoperative evaluation from, 36f
- Pressure cycled ventilator, 191
- P-R interval, 4
- Prolonged life support, cardiopulmonary/cerebral resuscitation with, 182–83
- Propofol (Diprivan, Rapinovet)
  - cardiovascular effects from, 215t
  - cerebral blood flow with injectable, 222
  - induction with, 146–47, 147t, 150t
  - liver disease pharmacology with, 260
  - pediatric patients induction with, 269, 270t
  - renal disease anesthesia with, 252, 253t
- PSGAG. *See* Polysulfated glycosaminoglycans
- Pulmonic stenosis, 211–12, 214t
- Pulse oximetry
  - equine anesthesia maintenance with, 369
  - factors influencing accuracy of, 96
  - interpretation of data from, 97
  - monitoring with, 95–97
  - patient assessment/treatment of decreased SpO<sub>2</sub> with, 97
  - physiology with, 95–96
  - types of, 96
    - reflectance probe, 96
    - transmittance probe, 96, 96f
  - working of, 95–96

- PVC. *See* Ventricular premature contraction
- P wave, 4, 86
- Pyometra, 310
- QRS complex, 4, 86
- Q-T interval, 4
- Rabbits, 319–22
  - anesthesia induction, care and support for, 320–22, 322f
  - anesthesia preparation for, 319–20
  - anesthesia recovery with, 322
  - emergency considerations for, 322
  - signs of acute pain in, 335f
- Radiography, 24
- Rapinivet. *See* Propofol
- Ravi-Ricci return-to-flow principle, 111, 112
- Rebreathing system, 80–81, 81f
  - pediatric circles in, 81
  - standard adult circles in, 81
- Record keeping, 35–39
  - anesthetic record, 35–37, 36f
    - automated, 37
    - handwritten monitoring grid, 37
    - information included in, 35
    - legal document, 37
  - controlled substances, 37–39, 39f
  - preoperative evaluation from, 36f
- Reexpansion pulmonary edema (RPE), 190
- Referred pain, 329
- Reflectance probe, 96
- Regenerative stem cell therapy (RSCT), 355
- Regurgitation, recovering patient with, 165
- Renal disease, 245–54
  - anesthesia for, 250–54, 253t, 254t
    - alpha-2 agonists, 251, 253t
    - anticholinergics, 251, 253t
    - barbiturates, 252, 253t
    - benzodiazepine, 251, 253t
    - COX inhibition, 254, 254t
    - nitrous oxide, 252, 253t
    - nonsteroidal antiinflammatory drugs (NSAID), 252–54, 253t
    - opioids, 251, 253t
    - phenothiazine, 251, 253t
    - propofol, 252, 253t
- Renal system
  - acid-base balance in, 249
  - anatomy of, 245–46, 246f
  - antidiuretic hormone in, 248–49
  - autoregulation in, 246
  - blood flow of, 246
  - juxtaglomerular apparatus in, 246–47, 248f
  - perfusion pressure in, 246
  - preanesthetic workup exam for, 18, 25f
  - renal function tests for, 249–50, 250t
    - blood urea nitrogen, 249
    - glomerular filtration rate, 249
    - serum creatinine, 22, 249
  - renin-angiotensin system, 246–48, 247f, 248f
- Renin-angiotensin system, 246–48, 247f, 248f
- Replacement fluid therapy, 126–27, 126f, 126t
- Resistance, 189
- Respiratory-challenged patients, 227–36
  - brachycephalic breeds' concern with, 231–32, 231f, 232f
  - desaturation with, 233–34
  - induction for, 229–30, 230t, 231t
    - fentanyl, 231t
    - hydromorphone, 231t
    - ketamine, 230t, 231t
    - lidocaine, 230t, 231t
    - morphine, 230t
    - oxymorphone, 231t
  - intrathoracic surgery for, 232–33
  - premedication for, 228–29
  - recovery/postop analgesia for, 234–36, 235t–236t, 236f
  - wound soaker protocol for, 235t–236t, 236f
- Respiratory rate, 188
- Respiratory system, 7–11
  - anatomic dead space of, 9, 10f
  - anatomy of, 7–11, 8f, 10f
    - alveolar-capillary membrane, 8
    - alveoli, 7, 8f
    - bronchi, 7
    - bronchioles, 7
    - capillaries, 8
  - dead space ventilation of, 9, 10f
  - positive end expiratory pressure of, 9
  - positive pressure ventilation of, 9
  - preanesthetic workup exam for, 18, 25f
- Resuscitation fluid therapy, 127
- Retrobulbar block, 198
- Rodents, 317–19
  - anesthesia induction, care and support for, 318–19, 319f
  - anesthesia preparation for, 317–18
  - anesthesia recovery with, 319
  - emergency considerations for, 322
  - signs of acute pain in, 335f
- RPE. *See* Reexpansion pulmonary edema
- RSCT. *See* Regenerative stem cell therapy
- Ruminant anesthesia, 373–84
  - intravenous regional anesthesia for, 376–77
    - digital blocks in cattle, 377
    - peroneal/tibial nerve blocks, 377
  - local analgesia/nerve blocks for, 374–76
    - auriculopalpebral nerve block, 374
    - caudal block, 375



- cornual nerve block, 374–75, 375f
  - epidural block, 375–76
  - preanesthetic preparation for, 378–84, 379t, 380f, 384f
  - sedatives/sedation agents for, 377–78
- SA node. *See* Sino-atrial node
- SaO<sub>2</sub>. *See* Oxygen saturation
- SCr. *See* Serum creatinine
- Sedation drugs, 135–42. *See also* Premedication drugs
- Semiclosed circle systems, 84
- Serum creatinine (SCr), 22, 249
- Sevoflurane, 157–58, 157f
  - cardiovascular effects from, 215t
  - inhalant anesthetics for ICP with, 223
  - minimum alveolar concentration of, 154t
  - vaporization pressure of, 155t
- Shock, 301–3
  - cardiogenic, 130
  - hypovolemic, 130
  - obstructive, 130
- Sidestream (diverting) monitor, 114–19
- Sino-atrial node (SA node), 3
- Sinus bradycardia, 88–89
- Sinus tachycardia, 88, 88f
- Smoke inhalation, 295–96, 296f
- SOAP, 24, 26f
- Sodium bicarbonate, cardiopulmonary/cerebral resuscitation with, 180t
- Solubility coefficient, 155, 155t
- Somatic pain, 328–29
- Stroke volume, 106, 106f
- Stylet and guide tubes, 62–63, 62f
- Subaortic stenosis, 210f
- Supraventricular arrhythmias (SVT), 213, 217t
- SVT. *See* Supraventricular arrhythmias
- Swallowing reflex, 101
- Systemic vascular resistance, 6
- Systolic blood pressure, 5, 6, 106, 107t
- Tachycardia
  - anesthesia complicated by, 173
  - sinus, 88, 88f
  - ventricular, 90–91, 90f, 173–74
- Telazol. *See* Tiletamine
- Therapeutic laser, pain management with, 354, 354f
- Thiobarbiturate (Thiopental)
  - cardiovascular effects from, 215t
  - induction with, 148–49
- Thiopental. *See* Thiobarbiturate
- Thoracic trauma, 295
- Thoracotomies, 227–36
  - brachycephalic breeds' concern with, 231–32, 231f, 232f
  - desaturation with, 233–34
  - induction for, 229–30, 230t, 231t
    - fentanyl, 231t
    - hydromorphone, 231t
    - ketamine, 230t, 231t
    - lidocaine, 230t, 231t
    - morphine, 230t
    - oxymorphone, 231t
  - premedication for, 228–29
  - recovery/postop analgesia for, 234–36, 235t–236t, 236f
  - wound soaker protocol for, 233t–234t, 234f
- Thrombocytopenic count, 23
- Tidal volume, 9, 188
- Tiletamine (Telazol), 137, 138
  - induction with, 145–46, 147t, 150t
- Time cycled ventilator, 191–92, 192f
- TIVA. *See* Total Intravenous Anesthesia
- Tolazoline-zolazepam, equine induction phase with, 365
- Total Intravenous Anesthesia (TIVA), 365–66
- Total peripheral resistance, 106
- Total plasma protein, 22
- Tracheal trauma, 294, 294f
- Tracheostomy, patient recovery with, 164
- Tramadol
  - adaptive pain management with, 350
  - pain management with, 352–53
- Tranquilization, recovering patient with, 165
- Tranquilizers, 136–37
- Transcellular fluid, 123
- Transfusions, 133–34, 133f
- Transmittance probe, 96, 96f
- Trauma patients, 293–300
  - case report for, 297–300, 298t
  - induction agents for, 296–97, 297t
  - types of trauma for, 294–96, 294f, 296f
    - blunt force trauma, 296
    - burn injuries/smoke inhalation, 295–96, 296f
    - ocular trauma, 294
    - thoracic trauma, 295
    - tracheal trauma, 294, 294f
- Tricuspid valve, 4
- T wave, 4, 86, 87f
- Ultrasonography, 24
  - Doppler, 111
- Urethral obstruction, 309–10
- Urinalysis, 23–24
- Urinary catheter, recovering patient with, 164–65
- Urine specific gravity (USG), 22
- USG. *See* Urine specific gravity
- Valium. *See* Diazepam
- Vaporization pressure, 155, 155t
  - desflurane, 155t
  - halothane, 155t

- isoflurane, 155t
- sevoflurane, 155t
- Vaporizers, 73–75, 74f, 75f
  - complications with, 168
- Vasopressin, cardiopulmonary/cerebral resuscitation with, 179, 180t
- Vecuronium, cerebral blood flow with injectable, 222–23
- Ventilation, 8
  - cardiac disease patient outcome with, 206
  - common terms with, 188–91
    - atelectasis, 8, 189
    - compliance, 189
    - functional residual capacity, 189
    - hyperventilation, 116f, 172, 188
    - hypocapnia, 188
    - hypoventilation, 115f, 171, 188–89
    - hypoxemia, 10, 172, 189
    - intermittent positive pressure ventilation, 188
    - resistance, 189
    - respiratory rate, 188
    - tidal volume, 9, 188
    - V/Q mismatch, 189
  - discontinuing support for, 194
  - equine anesthesia with, 371
  - equipment definitions with, 189–91
    - controlled ventilation, 189
    - inspiratory to Expiratory Ratio (I:E ratio), 190, 190f, 191
    - peak Inspiratory Pressure (PIP), 189–90
    - positive end expiratory pressure (PEEP), 9, 190
    - reexpansion pulmonary edema (RPE), 190
  - evaluation of efficiency with, 194
  - goals of, 187
  - manual v. mechanical, 187–88
  - presetting, 192–94
  - pressure testing for, 192–94
    - setup for, 192–94
    - techniques in small animal patients, 187–94
    - types of, 191–92
      - pressure cycled, 191
      - time cycled, 191–92, 192f
      - volume cycled, 191, 191f
- Ventricular fibrillation (V-fib), 91
  - anesthesia complicated by, 173–74
- Ventricular premature contraction (VPC), 90, 213, 217t
  - anesthesia complicated by, 173–74
- Ventricular tachycardia (V-tach), 90–91, 90f, 217t
  - anesthesia complicated by, 173–74
- Versed. *See* Midazolam
- Vetalar. *See* Ketamine
- Vetalar, Ketalean. *See* Ketamine
- V-fib. *See* Ventricular fibrillation
- Visceral pain, 326–27
- Volume cycled ventilator, 191, 191f
- VPC. *See* Ventricular premature contraction
- V/Q mismatch, 189
- V-tach. *See* Ventricular tachycardia
- WAG. *See* Waste anesthetic gas
- Waste anesthetic gas (WAG)
  - active system for, 76–77, 76f
  - passive system for, 76
  - removal equipment, 76–77, 76f
  - troubleshooting, 78
- Weight loss, pain management with, 356
- Whole blood, 130, 130f
- Withdrawal reflex, 101, 101f
- Xylazine, 137t, 138
  - equine preanesthetic sedative with, 362
- Zolazepam, 136–37
  - induction with, 145, 147t, 150t



